Study Type
Interventional
ongoing
The CAPTIVA study is a multicenter, randomized, double-blind, phase III trial aimed at comparing the efficacy and safety of different antithrombotic therapies in patients with symptomatic intracranial atherosclerotic stenosis (sICAS). The study involves three treatment arms: ticagrelor + aspirin, low dose rivaroxaban + aspirin, and clopidogrel + aspirin. The primary goal is to determine if the experimental arms (ticagrelor or rivaroxaban) are superior to the clopidogrel arm in reducing the 1-year rate of ischemic stroke, intracerebral hemorrhage (ICH), or vascular death.
The study also explores the impact of CYP2C19 loss-of-function carrier status on the efficacy of the treatments. The CAPTIVA study is funded by NIH/NINDS and involves collaboration across approximately 150 sites.
The trial is sponsored by the University of Florida, while PHRI is coordinating conduct of the trial in Canada at up to 30 sites with some supplementary support from CIHR.
Study Design
A two-stage Phase III, double-blind randomized trial
NO. of Countries
2
NO. of Sites
150
NO. of Participants
1683
Study Period
2022-2028
Sponsor
University of Florida
Kanjana Perera
Scientist
Kanjana Perera
Scientist
Kanjana (Sashi) Perera is a Scientist in the Brain Health and Stroke research program at PHRI, Assistant Professor, Medicine (neurology), McMaster University, and a stroke neurologist at Hamilton Health Sciences. Her main research focus is on secondary stroke prevention, cryptogenic stroke, and uncommon causes of stroke and the optimization of clinical care in this patient population.
She has served as Principal Investigator and Co-Investigator for Phase II and III clinical trials, and is on the adjudication committees for international multicenter stroke/cardiovascular trials. She has won research awards, and her work has been published in high-impact medical journals. She obtained her medical degree from Sri Lanka with Honors for academic excellence. She completed her training in Neurology at the University of Western Ontario in 2013 and subsequently pursued a fellowship in Stroke/Vascular Neurology at McMaster University.
Amanda Taylor
Associate Program Manager
Amanda Taylor
Associate Program Manager
Amanda Taylor is an Associate Program Manager who currently coordinates trials in stroke, and has experience conducting trials in acute coronary syndrome and arrhythmia. Amanda joined PHRI in 2007. She holds a Bachelor of Science Degree (Honours) in Neurobiology from Brock University.
Kevin Reeh
Project Manager
Kevin Reeh
Project Manager
Kevin Reeh has more than 15 years experience in academic research. He has been at PHRI since 2014, and has been involved in the coordination of large, multicenter international clinical trials, as well as pilot/feasibility studies. These project include industry-sponsored, and investigator-initiated with industry and/or grant funding.
He has Bachelor degrees in the Biological Sciences and Health Sciences from Brock University, as well as a Masters of Science from Dalhousie University.
National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
University of Cincinnati
Medical University of South Carolina
Janssen Scientific Affairs
AstraZeneca
Population Health Research Institute
ongoing
CoVasc-ICH 2
Brain Health & Stroke
Data indicate that patients with intracerebral hemorrhage (ICH) are at high risk for thromboembolic events...
ongoing
LEAST
Brain Health & Stroke
The overall goal of Liraglutide for patients receiving Endovascular Stroke Thrombectomy (LEAST) is to test...
ongoing
CoVasc-ICH
Brain Health & Stroke
With our aging demographics the burden of intracerebral hemorrhage (ICH) related morbidity and mortality, and...
